Press releases.

Press releases 2018

Press releases 2018

Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital

December 19th 2018

New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit

November 27th 2018

Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

November 12th 2018

Operational Update

November 1st 2018

Immutep Announces Data Presentations at Upcoming Industry Conferences

October 24th 2018

Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

October 2nd 2018

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

September 26th 2018

Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

September 24th 2018

Progress Towards Clinical Development of IMP761 - A LAG-3 Agonist Antibody

September 3rd 2018

Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government

August 21st 2018

Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference

August 16th 2018

TACTI-mel Patient Recruitment Complete and Operational Update

August 7th 2018

Immutep's LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA

July 30th 2018

Immutep Submits Investigational New Drug (IND) Application with FDA

July 2nd 2018

Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast

May 30th 2018

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast

May 17th 2018

Immutep to Present at 2018 ASCO Annual Meeting

May 4th 2018

Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million

April 12th 2018

Operational Update

April 2nd 2018

Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit

March 22nd 2018

Immutep Commences Patient Dosing In Additional TACTI-mel Cohort

March 21st 2018

Immutep Raises A$6.85M Through Institutional Placement

March 11th 2018

Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD

March 11th 2018

Immutep Announces United States Patent Grant for IMP701 Antibody

March 5th 2018

Immutep receives A$686,704 R&D Tax Incentive

March 4th 2018

Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial

February 8th 2018

Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma

January 31st 2018